Research programme: metalloproteinase inhibitors - OSI/Vernalis

Drug Profile

Research programme: metalloproteinase inhibitors - OSI/Vernalis

Alternative Names: Matrix metalloproteinase inhibitors research programme - OSI/Vernalis; Metalloprotease inhibitors research programme - OSI/Vernalis; Metalloproteinase inhibitors research programme - OSI/Vernalis; MMP inhibitors research programme - OSI/Vernalis; Research programme: matrix metalloproteinase inhibitors - OSI/Vernalis; Research programme: metalloprotease inhibitors - OSI/Vernalis; Research programme: MMP inhibitors - OSI/Vernalis

Latest Information Update: 06 Feb 2005

Price : $50

At a glance

  • Originator OSI Pharmaceuticals; Vernalis
  • Class
  • Mechanism of Action Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections; Inflammation; Rheumatic disorders

Most Recent Events

  • 14 Jan 2005 Discontinued - Preclinical for Rheumatic disorders in United Kingdom (unspecified route)
  • 14 Jan 2005 Discontinued - Preclinical for Inflammation in United Kingdom (unspecified route)
  • 14 Jan 2005 Discontinued - Preclinical for Bacterial infections in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top